Harmony Biosciences Holdings Inc. (HRMY) exhibits 77.2% gross margins and 63.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 7.8x enterprise multiple and 4.8% implied options volatility.
Sustained 77.2% gross profitability converts into 24.0% operating margin and 63.0% ROIC, outpacing sector cost of capital.
ROIC: 63.0% // GM: 77.2%YoY revenue trajectory of +21.5% paired with 15.48% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +21.5% // FCF YLD: 15.48%Altman Z-Score of 5.38 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.38 // F-SCORE: 9/9Trading at 14.2x trailing P/E (11.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 14.2x // EV/EBITDA: 7.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $38.59 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 18.3% net margins.
NET MARGIN: 18.3% // D/E: 0.17x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for HRMY & activate live FRED threshold breach alerts.